Mutual of America Capital Management LLC Grows Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Mutual of America Capital Management LLC grew its stake in DexCom, Inc. (NASDAQ:DXCM) by 3.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 57,138 shares of the medical device company’s stock after purchasing an additional 2,084 shares during the period. Mutual of America Capital Management LLC’s holdings in DexCom were worth $3,831,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of DXCM. Taylor Frigon Capital Management LLC boosted its holdings in DexCom by 51.6% during the 3rd quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after acquiring an additional 11,075 shares during the period. Brooktree Capital Management purchased a new position in shares of DexCom in the 3rd quarter valued at $683,000. National Pension Service raised its holdings in DexCom by 4.1% in the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock worth $63,671,000 after purchasing an additional 37,363 shares in the last quarter. Intact Investment Management Inc. bought a new position in shares of DexCom during the 3rd quarter worth approximately $650,000. Finally, Waters Parkerson & CO. LLC increased its position in shares of DexCom by 4.2% during the second quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock worth $30,912,000 after purchasing an additional 10,892 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This represents a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.56 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by company insiders.

DexCom Trading Down 1.0 %

Shares of DXCM stock opened at $74.48 on Friday. The stock has a 50 day simple moving average of $70.43 and a 200-day simple moving average of $90.34. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a market cap of $29.09 billion, a price-to-earnings ratio of 45.05, a PEG ratio of 2.30 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on DXCM. Royal Bank of Canada cut their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Stifel Nicolaus upped their target price on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, August 23rd. Morgan Stanley cut their price target on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a report on Friday, July 26th. UBS Group decreased their price objective on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Finally, Robert W. Baird boosted their target price on shares of DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, August 5th. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.